Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
저자
Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y-J.; Enzinger, P. C.; Ilson, D. H.; van Cutsem, E.; Gallego Plazas, J.; Huang, J.; Shen, L.; Oh, S. C.; Sunpaweravong, P.; Soo, H. H. F.; Turk, H. M.; Park, J. W.; Moran, D.; Bhattacharya, P.; Cao, Y. J.; Xu, R-H.